Af­ter two flops, Roche and Ex­elix­is post ear­ly PhI­II win for Tecen­triq/Cabome­tyx com­bo — but will wait for OS da­ta

Roche and Ex­elix­is have fi­nal­ly notched a Phase III win with the com­bi­na­tion of Tecen­triq and Cabome­tyx, clear­ing the pro­gres­sion-free sur­vival bar in metasta­t­ic cas­tra­tion-re­sis­tant prostate can­cer.

The com­pa­nies — along with ex-US part­ners at Ipsen and Take­da — have had lit­tle suc­cess with the drug com­bi­na­tion in sol­id tu­mors. Out of three piv­otal tri­als, Tecen­triq plus Cabome­tyx al­ready failed two, name­ly CON­TACT-01 in non-small cell lung can­cer and CON­TACT-03 in re­nal cell car­ci­no­ma.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER